Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

NOVEL POLYPHENOLS THAT INHIBIT COLON CANCER CELL GROWTH AFFECTING CANCER CELL METABOLISM.

Gomez de Cedron M, Vargas T, Madrona A, Jimenez A, Perez Perez MJ, Quintela JC, Reglero G, San-Felix AR, Ramirez de Molina A.

J Pharmacol Exp Ther. 2018 Jun 5. pii: jpet.118.248278. doi: 10.1124/jpet.118.248278. [Epub ahead of print]

2.

The role of glycosyltransferase enzyme GCNT3 in colon and ovarian cancer prognosis and chemoresistance.

Fernández LP, Sánchez-Martínez R, Vargas T, Herranz J, Martín-Hernández R, Mendiola M, Hardisson D, Reglero G, Feliu J, Redondo A, Ramírez de Molina A.

Sci Rep. 2018 May 31;8(1):8485. doi: 10.1038/s41598-018-26468-4.

3.

The transcriptional and mutational landscapes of lipid metabolism-related genes in colon cancer.

Fernández LP, Ramos-Ruiz R, Herranz J, Martín-Hernández R, Vargas T, Mendiola M, Guerra L, Reglero G, Feliu J, Ramírez de Molina A.

Oncotarget. 2017 Dec 21;9(5):5919-5930. doi: 10.18632/oncotarget.23592. eCollection 2018 Jan 19.

4.

Targeting the lipid metabolic axis ACSL/SCD in colorectal cancer progression by therapeutic miRNAs: miR-19b-1 role.

Cruz-Gil S, Sanchez-Martinez R, Gomez de Cedron M, Martin-Hernandez R, Vargas T, Molina S, Herranz J, Davalos A, Reglero G, Ramirez de Molina A.

J Lipid Res. 2018 Jan;59(1):14-24. doi: 10.1194/jlr.M076752. Epub 2017 Oct 26.

PMID:
29074607
5.

MicroRNA-661 modulates redox and metabolic homeostasis in colon cancer.

Gómez de Cedrón M, Acín Pérez R, Sánchez-Martínez R, Molina S, Herranz J, Feliu J, Reglero G, Enríquez JA, Ramírez de Molina A.

Mol Oncol. 2017 Dec;11(12):1768-1787. doi: 10.1002/1878-0261.12142. Epub 2017 Nov 6.

6.

Precision Nutrition for Targeting Lipid Metabolism in Colorectal Cancer.

Aguirre-Portolés C, Fernández LP, Ramírez de Molina A.

Nutrients. 2017 Sep 28;9(10). pii: E1076. doi: 10.3390/nu9101076. Review.

7.

Complementary ACSL isoforms contribute to a non-Warburg advantageous energetic status characterizing invasive colon cancer cells.

Sánchez-Martínez R, Cruz-Gil S, García-Álvarez MS, Reglero G, Ramírez de Molina A.

Sci Rep. 2017 Sep 11;7(1):11143. doi: 10.1038/s41598-017-11612-3.

8.

Lipidomics Insights in Health and Nutritional Intervention Studies.

Ibáñez C, Mouhid L, Reglero G, Ramírez de Molina A.

J Agric Food Chem. 2017 Sep 13;65(36):7827-7842. doi: 10.1021/acs.jafc.7b02643. Epub 2017 Sep 5. Review.

PMID:
28805384
9.

Improving In Vivo Efficacy of Bioactive Molecules: An Overview of Potentially Antitumor Phytochemicals and Currently Available Lipid-Based Delivery Systems.

Mouhid L, Corzo-Martínez M, Torres C, Vázquez L, Reglero G, Fornari T, Ramírez de Molina A.

J Oncol. 2017;2017:7351976. doi: 10.1155/2017/7351976. Epub 2017 May 7. Review.

10.

Lipid metabolism and lung cancer.

Merino Salvador M, Gómez de Cedrón M, Moreno Rubio J, Falagán Martínez S, Sánchez Martínez R, Casado E, Ramírez de Molina A, Sereno M.

Crit Rev Oncol Hematol. 2017 Apr;112:31-40. doi: 10.1016/j.critrevonc.2017.02.001. Epub 2017 Feb 13. Review.

PMID:
28325263
11.

Multiple chemical sensitivity: Genotypic characterization, nutritional status and quality of life in 52 patients.

Loria-Kohen V, Marcos-Pasero H, de la Iglesia R, Aguilar-Aguilar E, Espinosa-Salinas I, Herranz J, Ramírez de Molina A, Reglero G.

Med Clin (Barc). 2017 Aug 22;149(4):141-146. doi: 10.1016/j.medcli.2017.01.022. Epub 2017 Mar 7. English, Spanish.

PMID:
28283271
12.

Biological Activities of Asteraceae (Achillea millefolium and Calendula officinalis) and Lamiaceae (Melissa officinalis and Origanum majorana) Plant Extracts.

García-Risco MR, Mouhid L, Salas-Pérez L, López-Padilla A, Santoyo S, Jaime L, Ramírez de Molina A, Reglero G, Fornari T.

Plant Foods Hum Nutr. 2017 Mar;72(1):96-102. doi: 10.1007/s11130-016-0596-8.

PMID:
28101823
13.

3'UTR Polymorphism in ACSL1 Gene Correlates with Expression Levels and Poor Clinical Outcome in Colon Cancer Patients.

Vargas T, Moreno-Rubio J, Herranz J, Cejas P, Molina S, Mendiola M, Burgos E, Custodio AB, De Miguel M, Martín-Hernández R, Reglero G, Feliu J, Ramírez de Molina A.

PLoS One. 2016 Dec 19;11(12):e0168423. doi: 10.1371/journal.pone.0168423. eCollection 2016.

14.

Dietary Strategies Implicated in the Prevention and Treatment of Metabolic Syndrome.

de la Iglesia R, Loria-Kohen V, Zulet MA, Martinez JA, Reglero G, Ramirez de Molina A.

Int J Mol Sci. 2016 Nov 10;17(11). pii: E1877. Review.

15.

Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel.

Mendiola M, Martínez-Marin V, Herranz J, Heredia V, Yébenes L, Zamora P, Castelo B, Pinto Á, Miguel M, Díaz E, Gámez A, Fresno JÁ, Ramírez de Molina A, Hardisson D, Espinosa E, Redondo A.

Oncotarget. 2016 Apr 26;7(17):24217-27. doi: 10.18632/oncotarget.8128.

16.

Polymorphism in the CLOCK gene may influence the effect of fat intake reduction on weight loss.

Loria-Kohen V, Espinosa-Salinas I, Marcos-Pasero H, Lourenço-Nogueira T, Herranz J, Molina S, Reglero G, Ramirez de Molina A.

Nutrition. 2016 Apr;32(4):453-60. doi: 10.1016/j.nut.2015.10.013. Epub 2015 Nov 6.

PMID:
26690565
17.

Microtargeting cancer metabolism: opening new therapeutic windows based on lipid metabolism.

Gómez de Cedrón M, Ramírez de Molina A.

J Lipid Res. 2016 Feb;57(2):193-206. doi: 10.1194/jlr.R061812. Epub 2015 Dec 2. Review.

18.

Rosemary (Rosmarinus officinalis L.) Extract as a Potential Complementary Agent in Anticancer Therapy.

González-Vallinas M, Reglero G, Ramírez de Molina A.

Nutr Cancer. 2015;67(8):1221-9. doi: 10.1080/01635581.2015.1082110. Epub 2015 Oct 9. Review.

PMID:
26452641
19.

A link between lipid metabolism and epithelial-mesenchymal transition provides a target for colon cancer therapy.

Sánchez-Martínez R, Cruz-Gil S, Gómez de Cedrón M, Álvarez-Fernández M, Vargas T, Molina S, García B, Herranz J, Moreno-Rubio J, Reglero G, Pérez-Moreno M, Feliu J, Malumbres M, Ramírez de Molina A.

Oncotarget. 2015 Nov 17;6(36):38719-36. doi: 10.18632/oncotarget.5340.

20.

The ellagic acid derivative 4,4'-di-O-methylellagic acid efficiently inhibits colon cancer cell growth through a mechanism involving WNT16.

Ramírez de Molina A, Vargas T, Molina S, Sánchez J, Martínez-Romero J, González-Vallinas M, Martín-Hernández R, Sánchez-Martínez R, Gómez de Cedrón M, Dávalos A, Calani L, Del Rio D, González-Sarrías A, Espín JC, Tomás-Barberán FA, Reglero G.

J Pharmacol Exp Ther. 2015 May;353(2):433-44. doi: 10.1124/jpet.114.221796. Epub 2015 Mar 10.

21.

ColoLipidGene: signature of lipid metabolism-related genes to predict prognosis in stage-II colon cancer patients.

Vargas T, Moreno-Rubio J, Herranz J, Cejas P, Molina S, González-Vallinas M, Mendiola M, Burgos E, Aguayo C, Custodio AB, Machado I, Ramos D, Gironella M, Espinosa-Salinas I, Ramos R, Martín-Hernández R, Risueño A, De Las Rivas J, Reglero G, Yaya R, Fernández-Martos C, Aparicio J, Maurel J, Feliu J, Ramírez de Molina A.

Oncotarget. 2015 Mar 30;6(9):7348-63.

22.

Clinical relevance of the differential expression of the glycosyltransferase gene GCNT3 in colon cancer.

González-Vallinas M, Vargas T, Moreno-Rubio J, Molina S, Herranz J, Cejas P, Burgos E, Aguayo C, Custodio A, Reglero G, Feliu J, Ramírez de Molina A.

Eur J Cancer. 2015 Jan;51(1):1-8. doi: 10.1016/j.ejca.2014.10.021. Epub 2014 Nov 11.

PMID:
25466507
23.

Genes associated with metabolic syndrome predict disease-free survival in stage II colorectal cancer patients. A novel link between metabolic dysregulation and colorectal cancer.

Vargas T, Moreno-Rubio J, Herranz J, Cejas P, Molina S, González-Vallinas M, Ramos R, Burgos E, Aguayo C, Custodio AB, Reglero G, Feliu J, Ramírez de Molina A.

Mol Oncol. 2014 Dec;8(8):1469-81. doi: 10.1016/j.molonc.2014.05.015. Epub 2014 Jun 10.

24.

A genetic variant of PPARA modulates cardiovascular risk biomarkers after milk consumption.

Loria-Kohen V, Espinosa-Salinas I, Ramirez de Molina A, Casas-Agustench P, Herranz J, Molina S, Fonollá J, Olivares M, Lara-Villoslada F, Reglero G, Ordovas JM.

Nutrition. 2014 Oct;30(10):1144-50. doi: 10.1016/j.nut.2014.02.012. Epub 2014 Mar 12.

PMID:
24976416
25.

Expression of microRNA-15b and the glycosyltransferase GCNT3 correlates with antitumor efficacy of Rosemary diterpenes in colon and pancreatic cancer.

González-Vallinas M, Molina S, Vicente G, Zarza V, Martín-Hernández R, García-Risco MR, Fornari T, Reglero G, Ramírez de Molina A.

PLoS One. 2014 Jun 3;9(6):e98556. doi: 10.1371/journal.pone.0098556. eCollection 2014.

26.

Modulation of estrogen and epidermal growth factor receptors by rosemary extract in breast cancer cells.

González-Vallinas M, Molina S, Vicente G, Sánchez-Martínez R, Vargas T, García-Risco MR, Fornari T, Reglero G, Ramírez de Molina A.

Electrophoresis. 2014 Jun;35(11):1719-27. doi: 10.1002/elps.201400011. Epub 2014 Mar 20.

PMID:
24615943
27.

Dietary phytochemicals in cancer prevention and therapy: a complementary approach with promising perspectives.

González-Vallinas M, González-Castejón M, Rodríguez-Casado A, Ramírez de Molina A.

Nutr Rev. 2013 Sep;71(9):585-99. doi: 10.1111/nure.12051. Epub 2013 Aug 1. Review.

PMID:
24032363
28.

Antiproliferative effect of alkylglycerols as vehicles of butyric acid on colon cancer cells.

Molina S, Moran-Valero MI, Martin D, Vázquez L, Vargas T, Torres CF, Ramirez de Molina A, Reglero G.

Chem Phys Lipids. 2013 Oct-Nov;175-176:50-6. doi: 10.1016/j.chemphyslip.2013.07.011. Epub 2013 Aug 21.

PMID:
23973778
29.

Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts.

de la Cueva A, Ramírez de Molina A, Alvarez-Ayerza N, Ramos MA, Cebrián A, Del Pulgar TG, Lacal JC.

PLoS One. 2013 Jun 10;8(6):e64961. doi: 10.1371/journal.pone.0064961. Print 2013.

30.

Antitumor effect of 5-fluorouracil is enhanced by rosemary extract in both drug sensitive and resistant colon cancer cells.

González-Vallinas M, Molina S, Vicente G, de la Cueva A, Vargas T, Santoyo S, García-Risco MR, Fornari T, Reglero G, Ramírez de Molina A.

Pharmacol Res. 2013 Jun;72:61-8. doi: 10.1016/j.phrs.2013.03.010. Epub 2013 Apr 1.

PMID:
23557932
31.

Nutritional genomics for the characterization of the effect of bioactive molecules in lipid metabolism and related pathways.

Daimiel L, Vargas T, Ramírez de Molina A.

Electrophoresis. 2012 Aug;33(15):2266-89. doi: 10.1002/elps.201200084. Review.

PMID:
22887150
32.

Acid ceramidase as a chemotherapeutic target to overcome resistance to the antitumoral effect of choline kinase α inhibition.

Ramírez de Molina A, de la Cueva A, Machado-Pinilla R, Rodriguez-Fanjul V, Gomez del Pulgar T, Cebrian A, Perona R, Lacal JC.

Curr Cancer Drug Targets. 2012 Jul;12(6):617-24.

PMID:
22515519
33.

The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.

Al-Saffar NM, Jackson LE, Raynaud FI, Clarke PA, Ramírez de Molina A, Lacal JC, Workman P, Leach MO.

Cancer Res. 2010 Jul 1;70(13):5507-17. doi: 10.1158/0008-5472.CAN-09-4476. Epub 2010 Jun 15.

34.

Regulation of Akt(ser473) phosphorylation by choline kinase in breast carcinoma cells.

Chua BT, Gallego-Ortega D, Ramirez de Molina A, Ullrich A, Lacal JC, Downward J.

Mol Cancer. 2009 Dec 31;8:131. doi: 10.1186/1476-4598-8-131.

35.

Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment.

Gallego-Ortega D, Ramirez de Molina A, Ramos MA, Valdes-Mora F, Barderas MG, Sarmentero-Estrada J, Lacal JC.

PLoS One. 2009 Nov 12;4(11):e7819. doi: 10.1371/journal.pone.0007819.

36.

A critical role for choline kinase-alpha in the aggressiveness of bladder carcinomas.

Hernando E, Sarmentero-Estrada J, Koppie T, Belda-Iniesta C, Ramírez de Molina V, Cejas P, Ozu C, Le C, Sánchez JJ, González-Barón M, Koutcher J, Cordón-Cardó C, Bochner BH, Lacal JC, Ramírez de Molina A.

Oncogene. 2009 Jul 2;28(26):2425-35. doi: 10.1038/onc.2009.91. Epub 2009 May 18.

37.

Choline kinase alpha depletion selectively kills tumoral cells.

Bañez-Coronel M, Ramírez de Molina A, Rodríguez-González A, Sarmentero J, Ramos MA, García-Cabezas MA, García-Oroz L, Lacal JC.

Curr Cancer Drug Targets. 2008 Dec;8(8):709-19.

PMID:
19075594
38.

TWIST1 overexpression is associated with nodal invasion and male sex in primary colorectal cancer.

Valdés-Mora F, Gómez del Pulgar T, Bandrés E, Cejas P, Ramírez de Molina A, Pérez-Palacios R, Gallego-Ortega D, García-Cabezas MA, Casado E, Larrauri J, Nistal M, González-Barón M, García-Foncillas J, Lacal JC.

Ann Surg Oncol. 2009 Jan;16(1):78-87. doi: 10.1245/s10434-008-0166-x. Epub 2008 Nov 11.

PMID:
19002529
39.

Choline kinase as a link connecting phospholipid metabolism and cell cycle regulation: implications in cancer therapy.

Ramírez de Molina A, Gallego-Ortega D, Sarmentero-Estrada J, Lagares D, Gómez Del Pulgar T, Bandrés E, García-Foncillas J, Lacal JC.

Int J Biochem Cell Biol. 2008;40(9):1753-63. doi: 10.1016/j.biocel.2008.01.013. Epub 2008 Jan 19.

PMID:
18296102
40.

Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study.

Ramírez de Molina A, Sarmentero-Estrada J, Belda-Iniesta C, Tarón M, Ramírez de Molina V, Cejas P, Skrzypski M, Gallego-Ortega D, de Castro J, Casado E, García-Cabezas MA, Sánchez JJ, Nistal M, Rosell R, González-Barón M, Lacal JC.

Lancet Oncol. 2007 Oct;8(10):889-97.

PMID:
17851129
41.

Generation and characterization of monoclonal antibodies against choline kinase alpha and their potential use as diagnostic tools in cancer.

Gallego-Ortega D, Ramirez De Molina A, Gutierrez R, Ramos MA, Sarmentero J, Cejas P, Nistal M, González Barón M, Lacal JC.

Int J Oncol. 2006 Aug;29(2):335-40.

PMID:
16820874
42.

Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models.

Al-Saffar NM, Troy H, Ramírez de Molina A, Jackson LE, Madhu B, Griffiths JR, Leach MO, Workman P, Lacal JC, Judson IR, Chung YL.

Cancer Res. 2006 Jan 1;66(1):427-34.

43.

18F-choline images murine atherosclerotic plaques ex vivo.

Matter CM, Wyss MT, Meier P, Späth N, von Lukowicz T, Lohmann C, Weber B, Ramirez de Molina A, Lacal JC, Ametamey SM, von Schulthess GK, Lüscher TF, Kaufmann PA, Buck A.

Arterioscler Thromb Vasc Biol. 2006 Mar;26(3):584-9. Epub 2005 Dec 15.

44.

Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis.

Ramírez de Molina A, Gallego-Ortega D, Sarmentero J, Bañez-Coronel M, Martín-Cantalejo Y, Lacal JC.

Cancer Res. 2005 Jul 1;65(13):5647-53.

45.

Inhibition of choline kinase renders a highly selective cytotoxic effect in tumour cells through a mitochondrial independent mechanism.

Rodríguez-González A, Ramírez de Molina A, Bañez-Coronel M, Megias D, Lacal JC.

Int J Oncol. 2005 Apr;26(4):999-1008.

PMID:
15753995
46.

Influence of the linker in bispyridium compounds on the inhibition of human choline kinase.

Conejo-García A, Báñez-Coronel M, Sánchez-Martín RM, Rodríguez-González A, Ramos A, Ramírez de Molina A, Espinosa A, Gallo MA, Campos JM, Lacal JC.

J Med Chem. 2004 Oct 21;47(22):5433-40.

PMID:
15481981
47.
48.

Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression.

Ramírez de Molina A, Báñez-Coronel M, Gutiérrez R, Rodríguez-González A, Olmeda D, Megías D, Lacal JC.

Cancer Res. 2004 Sep 15;64(18):6732-9.

49.

From Ras signalling to ChoK inhibitors: a further advance in anticancer drug design.

Ramírez de Molina A, Rodríguez-González A, Lacal JC.

Cancer Lett. 2004 Apr 8;206(2):137-48. Review.

PMID:
15013519
50.

Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells.

Rodríguez-González A, Ramírez de Molina A, Fernández F, Ramos MA, del Carmen Núñez M, Campos J, Lacal JC.

Oncogene. 2003 Dec 4;22(55):8803-12.

PMID:
14654777

Supplemental Content

Loading ...
Support Center